NAS:ALNY (USA) Also Trade In: Brazil Germany Mexico UK

Alnylam Pharmaceuticals Inc $ 125.45 -0.21 (-0.17%)

Avg Vol (1m):
Market Cap $:
14.57 Bil
Enterprise Value $:
13.07 Bil
P/E (TTM):
Warning! GuruFocus has detected 2 Severe warning signs with ALNY. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

Alnylam Pharmaceuticals Inc News and Headlines -

GuruFocus Articles Total 24
  • 1
  • 2

The two companies will work together to develop new antibodies aimed at neutralizing the virus

GlaxoSmithKline (GSK) is betting big that a small San Francisco biotech company can successfully develop a treatment and vaccine against Covid-19. The British pharma giant has made a $250 million equity investment in Vir Biotechnology, Inc. (VIR), hoping Vir’s expertise in monoclonal antibody technology will lead to development of new antibodies that defuse the novel coronavirus.

In late March, Vir said it had identified a number of antibody candidates, two of which the company plans to test in a Phase 2 clinical trial in the next three to five months, according a news release.

Vir’s shares rallied on announcement of

183 Views    Barry Cohen    2020-04-08 14:19
Companies in race to find treatment for genetic disease that can cause lung and liver disease

Adopting the theory that two heads are better than one, a pair of former biotech rivals are teaming up to take on a third company that has a head start in the search for a treatment for a genetic disease that can cause lung and liver disease.

Alnylam Pharmaceuticals (ALNY) and Dicerna Pharmaceuticals (DRNA) have joined forces to challenge Arrowhead Pharmaceuticals (ARWR) as well as two other companies working on a treatment, Intellia Therapeutics (NTLA) and Vertex Pharmaceuticals (VRTX).

Evidently, investors believe that a rising tide lifts all boats since shares of all five companies were up Monday, with Arrowhead

147 Views    Barry Cohen    2020-04-06 21:26
Conglomerate has 15 drug development programs at companies under its wing

BridgeBio, a conglomerate made up of other companies specializing in genetic diseases, plans to go public with a $225 million initial public offering. This comes on the heels of a nearly $300 million financing round in January.

The company will trade on the Nasdaq under the ticker symbol BBIO. The IPO is being underwritten by J.P. Morgan, Goldman Sachs, Piper Jaffary and Mizuho Securities, among others.

Palo Alto, California-based BridgeBio is a four-year-old company that adopted a business model championed by the Sloan Business School of Management at the Massachusetts Institute of Technology. The company finds drugs to treat genetic

67 Views    Barry Cohen    2019-05-30 22:12
Fund releases 1st-quarter portfolio

The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) released its first-quarter portfolio this week, listing five new holdings.

Managed by Jason Kritzer and Samantha Pandolfi, the Boston-based fund invests heavily in the health care space. The portfolio managers look around the world for securities that are not only reasonably priced, but which they believe will grow in value over time.

Based on these criteria, the fund opened positions in Alexion Pharmaceuticals Inc. (ALXN), Fisher & Paykel Healthcare Corp. Ltd. (NZSE:FPH), Alnylam Pharmaceuticals Inc. (ALNY), Argenx SE (ARGX) and Sarepta Therapeutics Ltd. (SRPT) during the quarter.


386 Views    Sydnee Gatewood    2019-05-02 21:43
The height of folly

The height of folly.

That’s what I call it when people pay 100 times a company’s pre-share revenue to buy a stock. You see this behavior mostly with young biotechnology stocks and fledgling technology stocks.

Investors mentally build what economics professor Burton Malkiel called “castles in the sky” when they drool over the potential in these stocks.

Of course, it’s possible to luck out if you catch the “next NVidia” but the odds are strongly against you.

Over the years, beginning in 2000, I’ve written 14 columns warning against investing in these sky-high stocks. The stocks I warned against have

764 Views    John Dorfman    2019-02-19 20:42
Seattle Genetics tops the list

According to the GuruFocus All-In-One Screener, the following health care stocks are popular among guru investors.

Eight gurus are invested in Seattle Genetics Inc. (SGEN). The biotech company develops therapies for the treatment of cancer. It has a market cap of $12.41 billion. Its revenue of $575.66 million has climbed 26.40% over a 10-year period.

The stock is trading with a price-book ratio of 8.97. As of Friday, the price of $78 is 2.25% below its 52-week high and 61.34% above its 52-week low. Over the last 10 years, it has returned a gain of 551%.

The company’s largest

118 Views    Tiziano Frateschi    2018-09-17 20:26
Competition is expected to be tough

After 16 years of development and $2.5 billion in investments, Alnylam Pharmaceuticals Inc. (ALNY) brought the world’s first RNAi treatment, known as Onpattro, to market.

Despite this accomplishment, the company did not see a significant jump in its stock following the Food and Drug Administration's approval. In fact, Alnylam is down approximately 6% over the last three months.


Despite the cold market reaction, it is clear Alnylam is promising long term for several reasons. First, RNAi therapies in general show tremendous promise in treating diseases. Second, Alnylam is in the process of

65 Views    Maxwell Koobatian    2018-08-20 15:19
Firm's largest sales of the 1st quarter

Dodge & Cox, the investment firm founded by Van Duyn Dodge and E. Morris Cox, sold shares of the following stocks in the first quarter.

The firm trimmed its NetApp Inc. (NTAP) position by 96.41%, impacting the portfolio by -0.49%.


The company operates in the design, manufacturing and technical support of high-performance storage and data management solutions. It has a market cap of $18.95 billion and an enterprise value of $15.51 billion.

GuruFocus gives the company a profitability and growth rating of 7 out of 10. Its return on equity of -0.19% and return on

24 Views    Tiziano Frateschi    2018-05-15 19:14
Hope stocks. Fads. Castles in the sky

Hope stocks. Fads. Castles in the sky.

Those are the words I think of when I see a stock that sells for 100 times revenue or more. In my view, you almost have to be crazy to invest in them.

Over the years, a typical stock has usually sold for about 1.4 times revenue. In today’s rich market the prevailing ratio is 2.25. So, we’re talking about stocks that sell for 44 times prevailing valuations, which are themselves rich.

The vast majority of these stocks are biotech stocks, and proponents argue that they are worth the inflated multiples. These companies

1076 Views    John Dorfman    2018-02-26 17:52
The fund trimmed its UnitedHealth, Cigna, Eli Lilly holdings

The Vanguard Health Care Fund (Trades, Portfolio), which is managed by Jean Hynes, sold shares of the following stocks in the fourth quarter.

The fund's Becton, Dickinson and Co. (BDX) holding was closed, impacting the portfolio by -0.64%.


The medical technology company has a market cap of $55.38 billion and an enterprise value of $60.04 billion.

GuruFocus gives the company a profitability and growth rating of 9 out of 10. Its return on equity (ROE) of 10.57% and return on assets (ROA) of 3.70% are outperforming 53% of companies in the Global

84 Views    Tiziano Frateschi    2018-02-08 19:34
Amgen, Innoviva among stocks investors are buying

According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.

Twenty-two gurus are invested in Amgen Inc. (AMGN).

The biotechnology company has a market cap of $131.14 billion. Its revenue has grown 10.50% annually over the past 10 years.

The stock is trading with a price-earnings (P/E) ratio of 16.31. The current stock price of $180.65 is 5.47% below its 52-week high and 20.13% above its 52-week low. Over the past decade, it has returned a gain of 279%.

The company’s largest shareholder among the gurus is PRIMECAP Management (Trades, Portfolio)

244 Views    Tiziano Frateschi    2018-01-08 17:26
What the rolling NDA submission process looks like for patisiran

At the end of last week, Alnylam Pharmaceuticals Inc. (ALNY) announced it had initiated a rolling submission for a new drug application (NDA) rooted in an asset called patisiran. This is a drug that analysts expect could top out at more than $1 billion in annual sales for Alnylam if it is successful in garnering a regulatory greenlight from the U.S. Food and Drug Administration (FDA) and, as such, it is one that markets are keeping an eye on as strongly indicative of wider investor sentiment surrounding the company and its long-term prospects right now.

On the back of the

72 Views    George Ronan    2017-11-21 17:29
Leerink upgrades AbbVie to Outperform

Analysts have taken action on some health care stocks.

Among the health care companies that saw their stocks re-rated by investment banking and financial services companies are AbbVie (ABBV) and two mid-caps, bluebird bio (BLUE) and Alnylam Pharmaceuticals (ALNY).

The first stock of this short list of re-rated health care companies is AbbVie. According to, LEERINK Partners LLC – the health care specialized investment bank – upgraded shares of AbbVie from Market Perform to Outperform.

The U.S. global health care company that was originated in 2013 as Abbott Laboratories’ (ABT) spinoff and headquartered in Lake Bluff, Illinois,

137 Views    Alberto Abaterusso    2017-10-03 15:20
These stocks are beating the benchmark

According to GuruFocus' All-in-One Screener, the following are some of the stocks that have outperformed the Standard & Poor's 500 Index over the last 12 months and were bought by gurus during the last quarter.

Albemarle Corp. (ALB) with a market cap of $11.61 billion has outperformed the S&P 500 Index by 10.4% in the last year.

Albemarle manufactures engineered specialty chemicals for various end markets, including petroleum refining, consumer electronics, construction, automotive, lubricants and pharmaceuticals.

Its shares are trading with a price-book (P/B) ratio of 3.19. According to the discount cash flow (DCF) calculator, the company is overpriced

249 Views    Tiziano Frateschi    2017-06-27 20:10
Top insider buys of the week, including Monsanto, Alnylam Pharmaceuticals, Synergy Resources and Ferrellgas Partners

Largest Insider buys for Monsanto (MON), Alnylam Pharmaceuticals Inc. (ALNY), Synergy Resources Corp. (SYRG) and Ferrellgas Partners LP (FGP).

Monsanto Co-Director Charles S. McMillan Bought 3,500 Shares

Director of Monsanto Co. Charles S. McMillan bought 3,500 shares on Oct. 10 at a price of $102.11.

Monsanto is a leading American multinational agrochemical and agricultural biotechnology corporation that specializes in producing genetically engineered seeds. The company has a market cap of $44.68 billion. As of Oct. 14, it traded at $102.11.

On Sep. 14, 2016, the German chemical company Bayer announced that it would take over Monsanto as one of the

1081 Views    Shuda Xia    2016-10-16 22:35
Backtesting Ben Graham's Lost Formula strategy

Known as the “Father of Value Investing,” Benjamin Graham intelligently invested money in the stock market.

Throughout his investing career, Graham explored several investing strategies to search for company stocks trading at deep prices and discussed the principles of safe investing in his financial books and teachings. During his final three years, the intelligent investor introduced a simple formula for searching bargain stocks: a trailing 12-month price-earnings (P/E) ratio between 7 and 10 and an equity-asset ratio at least 0.5.

Backtesting feature identifies top investing strategies

As discussed in the new feature announcement, the Backtesting feature allows

653 Views    James Li    2016-09-13 19:48
5 micro-caps purchased by gurus during 4th quarter

Much like small-cap stocks, micro-caps offer a chance of a high return, but also present more risk and volatility. Micro-caps are generally defined as companies with a capitalization between $50 million and $300 million.

The All-in-One Screener offers more than 150 filters to sort stocks, including a filter to sort by market cap. The following five stocks were some of the most popular micro-caps purchased by the gurus during the fourth quarter.

Liberty Broadband Corp. (LBRDK)

Liberty Broadband is a holding company that provides digital cable services. Four gurus added to their stakes in the company during the fourth quarter,

1845 Views    Sheila Dang    2016-04-04 22:29
A look into a few companies with significant insider transactions during the past week

According to GuruFocus Insider Data, the largest insider sells during the past week were: Facebook Inc. (FB), PacWest Bancorp (PACW), Waste Management Inc. (WM) and Alnylam Pharmaceuticals Inc. (ALNY).

The overall trend of insiders is illustrated in the chart below:

Facebook Inc.: Director Marc L. Andreessen sold 589,443 shares

Director Marc L. Andreessen sold 589,443 shares during the past week at an average price of $104.04. Andreessen owns at least 167,868 shares after this, and the price of the stock has decreased by 4.3% since.

Facebook has a market cap of $294.22 billion,

658 Views    Jimmy Xiao    2015-11-17 15:50
He also sells out Alibaba and starts a position in DeVry

Julian Robertson (Trades, Portfolio) is considered the father of hedge funds. He launched his firm Tiger Management in 1980 with $8 million and turned it into more than $22 billion in the late 1990s.

He manages a portfolio composed of 48 stocks with a total value of $708 million; the following are the largest trades he did during the second quarter.

He increased his stake in Inc. (JD) by 632.94% with an impact of 13.04% on his portfolio.

The company is an online direct sales company in China. It provides consumers

2218 Views    Tiziano Frateschi    2015-10-06 17:44

As the founder of one of the earliest hedge funds, Julian Robertson (Trades, Portfolio) is a pioneer in the world of investing. Robertson made 16 new buys in the first quarter, two of which were significant enough to join the 10 most valuable stakes in his portfolio. Now retired, Robertson invests in hedge funds that are often run by his former employees.

Robertson's net worth has been estimated at nearly $3.5 billion.

In the first quarter of 2015, he added 16 stakes to his portfolio.

Allergan PLC (AGN), a global pharmaceutical company with headquarters in Dublin, Ireland

4253 Views    David Goodloe    2015-06-23 21:39

Headlines Total 161
  • 1
  • 2

2020-11-25 $ 125.45 (-0.17%)
2020-11-20 $ 124.7 (0.72%)
2020-11-09 $ 127.48 (-2.49%)
2020-11-06 $ 130.73 (-5.17%)
2020-11-05 $ 137.86 (-1.17%)
2020-11-04 $ 139.49 (8.09%)
2020-11-03 $ 129.05 (3.31%)
2020-11-02 $ 124.91 (1.58%)
2020-10-29 $ 123.32 (-1.25%)
2020-10-28 $ 124.88 (-1.53%)
2020-10-27 $ 126.82 (-1.44%)
2020-10-26 $ 128.67 (-2.4%)
2020-10-22 $ 134.3 (-1.6%)
2020-10-19 $ 140.64 (-3.27%)
2020-10-01 $ 143.74 (-1.28%)
2020-09-30 $ 145.6 (0.41%)
2020-09-15 $ 130.51 (-0.37%)
2020-09-09 $ 123.06 (0.06%)
2020-08-27 $ 133.05 (%)
2020-08-21 $ 136.6 (0.18%)
2020-08-07 $ 143.53 (-0.41%)
2020-08-06 $ 144.12 (-4.2%)
2020-07-30 $ 151.11 (0.37%)
2020-07-15 $ 158.02 (0.5%)
2020-07-14 $ 157.23 (2.94%)
2020-07-10 $ 162.25 (2.02%)
2020-06-23 $ 151.83 (-0.76%)
2020-06-17 $ 136.67 (3.33%)
2020-06-12 $ 125.39 (-0.41%)
2020-06-08 $ 130.44 (2.23%)
2020-06-05 $ 127.59 (-3.27%)
2020-05-29 $ 135.27 (1.63%)
2020-05-27 $ 133.35 (-2.26%)
2020-05-25 $ 140.52 (%)
2020-05-22 $ 140.52 (-0.94%)
2020-05-21 $ 141.86 (-1.11%)
2020-05-16 $ 139.28 (2.26%)
2020-05-11 $ 142.43 (4.63%)
2020-05-08 $ 136.13 (-3.76%)
2020-05-07 $ 141.45 (-2.63%)
2020-05-06 $ 145.27 (2.86%)
2020-05-05 $ 141.23 (3.37%)
2020-05-04 $ 136.63 (5.94%)
2020-04-29 $ 135.81 (-1.23%)
2020-04-28 $ 137.5 (-3.64%)
2020-04-27 $ 142.7 (-2.01%)
2020-04-24 $ 145.63 (2.82%)
2020-04-22 $ 140.11 (1.64%)
2020-04-15 $ 121.5 (0.65%)
2020-04-14 $ 120.72 (1.44%)
2020-04-13 $ 119.01 (2.26%)
2020-04-08 $ 111.39 (1.71%)
2020-04-07 $ 109.52 (-2.34%)
2020-04-06 $ 112.14 (5.97%)
2020-02-24 $ 122.29 (-6.67%)
2020-02-21 $ 131.03 (-1.57%)
2020-02-14 $ 128.7 (-1.08%)
Total 161
  • 1
  • 2